2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma

Phase 1positiveIBI3003Positive

AI Analysis

Summary

Innovent Biologics announced updated Phase 1 clinical data for trispecific antibody IBI3003 targeting GPRC5D/BCMA/CD3 in patients with relapsed or refractory multiple myeloma, presented at the 2026 IMS conference.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Updated Phase 1 clinical data presented

Importance:5/10

Sentiment:

0.60

oncologymultiple myelomatrispecific antibodyGPRC5DBCMACD3clinical dataconference presentation

Related Companies

$DFPH $CHHE

Read the original article

Published by PR Newswire Pharma on September 29, 2026 7:45 AM

Read Original